TYK2 Inhibitors Selective Binding JAK Family
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for TYK2-mediated disorders lack selective inhibitors that effectively target TYK2 without causing off-target effects associated with JAK2 inhibition, necessitating the development of novel compounds with improved pharmacological properties.
Innovation Solution
Development of compounds of Formula (I) and their pharmaceutically acceptable salts, stereoisomers, or solvates, which selectively inhibit TYK2, potentially treating autoimmune, inflammatory, proliferative, endocrine, neurological disorders, and cancer by specifically targeting TYK2 pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing JAK inhibitors are used to treat TYK2-mediated disorders, then TYK2 activity is inhibited, but off-target effects occur due to JAK2 inhibition
Solution Approach 1:
The patent applies segmentation by designing inhibitors that selectively target TYK2 among the JAK family members (JAK1, JAK2, JAK3, TYK2). The compounds are structurally divided into specific moieties (e.g., heteroaryl groups, linker regions, and terminal groups) that enable selective binding to TYK2's unique binding pocket, thereby achieving segment-specific inhibition of TYK2 while sparing other JAK kinases.
Solution Approach 2:
The patent employs local quality by optimizing specific regions of the inhibitor molecule to interact with unique structural features of TYK2. The compounds contain specific functional groups (e.g., heteroatoms, substituted aromatic rings) positioned to form selective interactions with TYK2's activation loop and ATP-binding site, creating localized high-affinity binding that distinguishes TYK2 from other JAK family members.
2Object-affected harmful factors
If selective TYK2 inhibitors are developed, then off-target effects are reduced, but compound design complexity increases
Solution Approach 1:
The patent achieves universality by creating a platform of compounds with a common core structure (Formula I) that can be systematically varied to target TYK2. The general formula encompasses multiple specific embodiments with different heteroaryl groups, linkers, and terminal substituents, providing a universal framework that balances selectivity requirements with design efficiency.
Solution Approach 2:
The patent applies parameter changes by systematically varying molecular parameters within Formula I, such as the type of heteroaryl group (pyridyl, pyrimidinyl, triazolyl), the nature of substituents (halogen, alkyl, oxy groups), and the linker structure. These controlled parameter variations allow optimization of TYK2 selectivity while maintaining a manageable design space through defined structural constraints.
Data Source
AI summary
Described herein are compounds of Formula (I) that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.